This project is designed to provide genomics information on a variety of commonly prescribed drugs to determine how genomics data provided to the clinician can change the care provided to the patient as well as the economics of the drugs prescribed by using clinical decision support rules and genomic lab results in both general and specific alerts through the electronic medical record.
Regenstrief investigator Dr. Paul Dexter and Dr. Todd Skaar were recently awarded a 5-year extension for this research from the National Human Genome Research Institute through its Implementing Genomics in Practice (IGNITE) Network.
A previous five-year study known as the INGENIOUS Trial (2014-2018) was initiated by the late Dr. David Flockhart and led by Dr. Skaar and Dr. Dexter. It evaluated the economic and clinical outcomes associated with embedding a pharmacogenomics program in Eskenazi Health, a system that serves as a health care safety-net in Indianapolis, Indiana.
